A recent small study suggests that immunotherapy may benefit patients with refractory pancreatic or biliary cancer who have inherited a mutation in the homologous recombination deficiency (HRD) genes, BRCA1, BRCA2, and RAD51C.
Another new study reported that in BRCA1/2 carriers with pancreatic cancer, maintenance treatment with Olaparib may be of benefit. Findings showed that with Olaparib, long-term survival was more common and time to subsequent therapy was prolonged.
1. Terrero et al. JAMA Oncol. 2022;8(6):1-3. PMID: 35175286. Social media post June 13th, 2022. Available at: https://tinyurl.com/post6132022;
2 Kindler et al. J Clin Oncol. 2022;JCO2101604. PMID: 35834777. Social media post August 5th, 2022. Available